Abstract
Chronic migraine is a debilitating headache, whose treatment is often complicated by the concomitant overuse of symptomatic medication and by the poor efficacy of standard prophylactic treatments. The PREEMPT studies have demonstrated the efficacy and tolerability of onabotulinum toxin A (Botox®) in the treatment of this headache type. Data about its use in clinical practice are still scarce. Our study evaluated all subjects with chronic migraine who were treated with onabotulinum toxin A between February 2014 and November 2015 at the Parma Headache Centre. Botox was injected according to the PREEMPT paradigm every 3 months. The data about variations in the number of headache days and in symptomatic medication intake before and after the Botox injections were collected from the patients’ headache diaries. The study also evaluated tolerability to treatment, disability, and depressive symptoms. Of the 52 treated subjects, 14 received Botox treatment for at least 9 months and showed a significant decrease in the median number of headache days (from 19 to 14.5, p = 0.011) and in the median number of days of symptomatic medications intake and symptomatic drugs. Overall, the treatment was well tolerated. The average MIDAS and BDI-II scores after 9 months were reduced, though not significantly. The treatment with Botox proved effective and well tolerated in our clinical practice. Further studies on larger patient samples will help shed light on the persistence of the drug’s effect at long term and identify the predictive factors of response to treatment.
Similar content being viewed by others
References
Headache Classification Committee of the International Headache Society (IHS) (2013) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 33:629–808
Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, Lipton RB (2010) Global prevalence of chronic migraine: a systematic review. Cephalalgia 30:599–609
Lipton RB (2011) Chronic migraine, classification, differential diagnosis, and epidemiology. Headache 51(Suppl. 2):77–83
Buse DC, Manack AN, Fanning KM et al (2012) Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache 52(10):1456–1470
Straube A, Pfaffenrath V, Ladwig KH, Meisinger C, Hoffmann W, Fendrich K, Vennemann M, Berger K (2010) Prevalence of chronic migraine and medication overuse headache in Germany—the German DMKG headache study. Cephalalgia 30:207–213
Bigal ME, Serrano D, Reed M, Lipton RB (2008) Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 71:559–566
Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF (2010) PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30:793–803
Diener HC, Dodick DW, Aurora SK, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF (2010) PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30:804–814
Dodick D, Turkel C, De Gryse R et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: pooled results from double blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 50:921–936
Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ (2010) Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache 50:1406–1418
D’Amico D, Mosconi P, Genco S et al (2001) The migraine disability assessment (MIDAS) questionnaire: translation and reliability of the Italian version. Cephalalgia 21:947–952
Beck AT, Steer RA, Ball R, Ranieri W (1996) Comparison of beck depression inventories-IA and -II in psychiatric outpatients. J Pers Assess 67(3):588–597
Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C (2005) Botulinum toxin type A (BOTOX®) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 45:293–307
Grazzi L, Usai S (2015) Onabotulinum toxin A (Botox®) for chronic migraine treatment: an Italian experience. Neurol Sci 36(Suppl 1):S33–S35
Pedraza MI, de la Cruz C, Ruiz M, López-Mesonero L, Martínez E, de Lera M, Guerrero ÁL (2015) OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm. Springerplus 4:176
Rothrock J, Bloudek LM, Rothrock DA, Varon SF (2014) Real world economic impact of onabotulinum toxin A in patients with chronic migraine. Headache 54:1565–1573
Khalil M, Zafar HW, Quarshie V, Ahmed F (2014) Prospective analysis of the use of OnabotulinumtoxinA (BOTOX®) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K. J Headache Pain 15:54
Lin KH, Chen SP, Fuh JL, Wang YF, Wang SJ (2014) Efficacy, safety and predictors of response to botulinum toxin type A in refractory chronic migraine: a retrospective study. J Chin Med Assoc 77(1):10–15
Boudreau GP, Grosberg BM, McAllister PJ, Lipton RB, Buse DC (2015) Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: an open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxiety. Int J Gen Med 9:79–86
Cernuda-Morollón E, Ramón C, Larrosa D, Alvarez R, Riesco N, Pascual J (2015) Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: what happens after 1 year? Cephalalgia 35(10):864–868
Negro A, D’Alonzo L, Lala N, Martelletti P (2015) A 2-year prospective evaluation study on onabotulinumtoxinA 155 U in chronic migraine. J Headache Pain 16(Suppl 1):A137
Acknowledgments
Thanks to Paolo Casimiro, MD, for his help with data collection.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Russo, M., Manzoni, G.C., Taga, A. et al. The use of onabotulinum toxin A (Botox®) in the treatment of chronic migraine at the Parma Headache Centre: a prospective observational study. Neurol Sci 37, 1127–1131 (2016). https://doi.org/10.1007/s10072-016-2568-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-016-2568-z